SPECIAL NOTICE
65 -- Human small airway epithelial cell (COVID-19)
- Notice Date
- 4/21/2022 2:11:45 PM
- Notice Type
- Special Notice
- NAICS
- 325414
— Biological Product (except Diagnostic) Manufacturing
- Contracting Office
- NATIONAL INSTITUTES OF HEALTH NIDA Bethesda MD 20892 USA
- ZIP Code
- 20892
- Response Due
- 4/28/2022 12:00:00 PM
- Point of Contact
- Michelle Cecilia, Phone: 3018277199
- E-Mail Address
-
michelle.cecilia@nih.gov
(michelle.cecilia@nih.gov)
- Small Business Set-Aside
- SBA Total Small Business Set-Aside (FAR 19.5)
- Description
- PRE-SOLICITATION NOTICE OF INTENT NON-COMPETITIVE Notice of Intent: 75N95022Q00204 INTRODUCTION PURSUANT TO FAR Subpart 5.2�Synopses of Proposed Contract Actions, THIS IS A PRE- SOLICITATION NOTICE OF A PROPOSED CONTRACT TO ACTION. THIS IS A PRE-SOLICITATION NON-COMPETITIVE NOTICE OF INTENT TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). The National Institute on Drug Abuse (NIDA), Office of Acquisitions, Contracts Management � Branch Blue, NCATS Section on behalf of the National Center for Advancing Translational Sciences intends to negotiate and award a contract for Full Saturation Regulatory Study for a lead D3 antagonist. NORTH AMERICAN INDUSTRY CLASSIFICATION SYSTEM (NAICS) CODE The intended procurement is classified under NAICS Code 325414: Biological Product (except Diagnostics) Manufacturing with a Size Standard of 1,250 employees. REGULATORY AUTHORITY The resultant contract will include all applicable provisions and clauses of the Federal acquisition Regulation (FAR) in effect through the Federal Acquisition Circular 2022-04, dated � January 30, 2022. STATUTORY AUTHORITY This acquisition is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13�Simplified Acquisition Procedures, Subpart 13.106-1 (b) (1), Soliciting from a single source. DESCRIPTION OF REQUIREMENT Project Description Human small airway epithelial cell is an essential cellular component for building in-vitro three-dimensional vascularized lung tissue for SARS-COV2 infection. It has been challenging to secure epithelial cell sources to improve robustness of the protocol for engineering 3D vascularized lung tissue to model respiratory virus infection such as SARS-COV2. Thus, this acquisition of small airway epithelial cells, which we previously confirmed with barrier functions and morphology, allows us to improve our tissue quality control and expand our current 3D lung tissue models for drug development. Lung is a primary infection site of respiratory viruses and studying the viral tropism is highly demanding physiologically relevant human in vitro model to develop better therapeutics. NCATS Tissue bioprinting lab has established a protocol for 3D vascular lung tissue model containing small airway epithelial cells, endothelial cells, pericytes, and fibroblasts. The inclusion of the small airway epithelial cells will allow for measuring barrier functions responding to various environmental cues during progression and initiation of respiratory viral infections such as Influenza virus and SARS-COV2 virus. NCATS Tissue bioprinting lab has been using the small airway cells for 5 years and confirmed that it met the desired outcomes. General Requirements Independently and not as an agent of the Government, the Contractor shall furnish all the necessary services, qualified, personnel, material, equipment, and facilities not otherwise provided by the Government as needed to perform the Specific Requirements below: Purchase Description See Attached Period of Performance The period of performance is from May 6, 2022 � September 30, 2022.� CLOSING STATEMENT This synopsis is not a request for competitive proposals. However, interested parties may identify their interest and capability to respond to this notice. The respondents must submit clear and convincing evidence that their product is equivalent or superior to the product specified in this notice. The response shall include: the unit price, list price, shipping and handling costs, delivery days after contract award, delivery terms, prompt payment discount terms, F.O.B. Point (Destination or Origin), product or catalog number(s); product description; and any other information or factors that may be considered to determine the method of acquisition. The response must also indicate the country of manufacturer of components and country of assembly (not necessary for IT purchases). A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will normally be considered solely for the purposes of determining whether to proceed on a non- competitive basis or to conduct a competitive procurement. All responses must be received by April 28, 2022 at 3:00 PM Eastern Time and must reference number 75N95022Q00204. Responses must be submitted electronically to Michelle Cecilia, Contract Specialist, at michelle.cecilia@nih.gov, and must reference the solicitation number 75N95022Q00204, on your electronic request. FAX requests are not accepted. �All responsible sources may submit a capability statement, proposal, or quotation, which shall be considered by the agency.� The purpose of this acquisition is in accordance with the Public Health Emergency declaration made January 31, 2020 and the National Emergency declaration made March 13, 2020 in response to Coronavirus (COVID-19).
- Web Link
-
SAM.gov Permalink
(https://sam.gov/opp/cf58ee9a42d64c5cb0ad20157fd80386/view)
- Place of Performance
- Address: Frederick, MD 21704, USA
- Zip Code: 21704
- Country: USA
- Zip Code: 21704
- Record
- SN06303936-F 20220423/220421230111 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |